MedTrace Logo

Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia

NCT00148616 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-06-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.

Conditions

  • Chronic Schizophrenia

Interventions

DRUG

Memantine

Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone

DRUG

Placebos

Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • M. Schaefer, MD

    lead OTHER

Principal Investigators

  • Martin Schaefer, MD · Charite Campus Mitte; Dept. of Psychiatry and Psychotherapy and Department of Psychiatry, Kliniken Essen-Mitte, Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2008-06-30
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148616 on ClinicalTrials.gov